US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.16 against a street estimate of 0.10 — a beat of 60.0%.
Analysts rate Azenta Inc a hold (2 buy, 5 hold, 0 sell out of 7) with an average price target of $35.25.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.35% |
| Politan Capital Management LP | 10.55% |
| Vanguard Portfolio Management, LLC | 5.59% |
| Vanguard Capital Management, LLC | 4.17% |
| Massachusetts Financial Services Company | 4.08% |
| State Street Corp | 4.02% |
| D. E. Shaw & Co LP | 3.06% |
| Dimensional Fund Advisors, Inc. | 2.81% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 FY2026 AZENTA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company received full USD 63,000,000 purchase price for B Medical Systems sale in cash on Septemb | 2026-09-04 |
| Board / officer change · Q4 FY2026 AZENTA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Board size reduced from 9 to 8 members following leadership change on August 22, 2026 • No financ | 2026-08-24 |
| Board / officer change · Q4 FY2026 AZENTA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • New executive appointment effective August 31, 2026: Erik J. Bello joins as Vice President, Chief | 2026-08-11 |
| Quarterly report · Q3 FY2026 AZENTA, INC. — Q3 2026 (ENDED JUNE 30, 2026) SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Total Revenue (9 months): $454.6 million vs. $434. | 2026-08-06 |
| Results announced · Q4 FY2026 AZENTA Q3 FISCAL 2026 RESULTS SUMMARY HEADLINE NUMBERS • Q3 revenue from continuing operations: $161 million, up 12% year-over-year • Q3 organic rev | 2026-08-04 |
| Quarterly report · Q2 FY2026 AZENTA, INC. - FORM 10-Q SUMMARY Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Total Revenue (6 months): $293.4 million (vs. $290.8 million p | 2026-05-08 |
| Quarterly report · Q1 FY2026 AZENTA, INC. – Q1 FY2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (Q1 FY2026): $148.6 million vs. $147.4 million prior year (Q1 FY2025) – essen | 2026-02-05 |
| Proxy statement · Q2 FY2026 AZENTA, INC. PROXY STATEMENT SUMMARY FOR RETAIL INVESTORS CEO COMPENSATION • John Marotta (CEO) total compensation in fiscal 2025: Not specified in | 2025-12-18 |
Readable in the app.
| Announcement | Date |
|---|---|
| Subsidiary provides $35M vendor loan to facilitate B Medical Systems acquisition Azenta completed the sale of B Medical Systems on July 1, 2026, for $63 million. The buyer, Thelema S.à r.l., paid $28 million in cash and received a $35 million vendor loan (financing provi | 2026-07-08 |
| Completes strategic acquisition of UK Biocentre Limited to expand biorepository capabilities Azenta completed its acquisition of UK Biocentre Limited for £20.5 million (plus up to £1.8 million in contingent payments), a UK-based provider of sample management, storage, and processing | 2026-03-04 |
| Sale and purchase agreement for entire issued share capital of B Medical Systems Azenta, Inc. has agreed to sell its entire stake in B Medical Systems S.à r.l. to Thelema S.à r.l., a Luxembourg-based company, through its German subsidiary Azenta Germany GmbH. The transac | 2025-12-29 |
| Board approves $250 million share repurchase program through 2028 Azenta's Board of Directors authorized a $250 million share repurchase program, effective December 9, 2025, through December 31, 2028. The company can buy back its own stock through open mar | 2025-12-10 |
| FY2026 organic revenue growth 3-5% with EBITDA margin expansion Azenta, a life sciences company, reported fiscal 2025 results showing modest but steady progress with improving profitability. Revenue grew 4% year-over-year to $594 million (3% organic grow | 2025-11-21 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Azenta Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.